e.l.f. Beauty, Inc.
ELFe.l.f. Beauty, Inc.'s price has outrun its earnings. −24.5% in a year against EPS −77.1% — the market is paying now for delivery later.
The sharpest disagreement: the price moved −24.5% in a year while annual EPS moved −77.1% — the difference is re-rating, and re-rating has to be repaid with earnings.
The price is topping out (2 weeks in) while the P/E sits at the 100th percentile of its own 4-year range. Underneath, the last four quarters read deteriorating — profit −266.7% year on year, and 152% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
e.l.f. Beauty, Inc. trades at $87.8, losing momentum at the top and 2 weeks into that stage. That is +14.1% against its own 200-day average. It sits at 42% of a 52-week range of $50 to $140. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 6 straight weeks.
Today the stock is losing momentum at the top — week 2 of stage 3. At $87.8 it trades +14.1% versus its 200-day average and sits at 42% of its 52-week range ($50–$140).
Against the market, two honest reads. Cumulative: over the last 9.9 years the stock moved +247% while the S&P 500 moved +257% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 6 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
e.l.f. Beauty, Inc. trades at 199.6× P/E, about the priciest it has ever traded. Its long-run median P/E is 69.5×, measured across 4.3 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 199.6× is about the priciest it has ever traded, against a long-run median of 69.5× measured over 4.3 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved −77.1% against a −24.5% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 3y, of the −11.8%/yr price move, ~−36.2%/yr came from earnings growth and ~+24.4 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Deteriorating Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
e.l.f. Beauty, Inc. reads as deteriorating on its fundamental arc. Deteriorating — profit and EPS growth are shrinking (profit growth −83.3% latest against +300.0% at its 12-quarter best), ROCE slipping at 5.1%. The read is built from 12 quarters across 4 curves, on full evidence.
🚨 Why it matters: falling curves mean every cheap-looking ratio below needs a discount for direction.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +25.2% | +41.4% | — | — |
| Profit | −72.7% | −20.6% | — | — |
| EPS | −77.1% | −26.5% | — | — |
| Stock price | −24.5% | −11.8% | +24.0% | +13.2% |
4-Factor Sector Score
31.6/100 — rank 17 of 20 in Household & Personal Products · 81% evidence confidence
e.l.f. Beauty, Inc. scores 31.6 out of 100 against the 20 companies it is compared with in Household & Personal Products, ranking 17. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 11.5 + 6.9 + 3.8 + 9.4 = 31.6. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
e.l.f. Beauty, Inc. reported $0.5 B of revenue in the Mar 26 quarter, +36.4% year on year. That is the 12th straight quarter of year-on-year growth. Over 4 years it has compounded at 43.2% a year. The last full year, FY26, came in at $1.6 B. The last four reported quarters add to $1.6 B.
FY26 revenue came in at $1.6 B (+25.2% on the year), capping 4 years at 43.2% compound. The latest quarter (Mar 26) printed $0.5 B, +36.4% year on year — the 12th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +23.8% growth against the decade's 43.2% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +24.4% over the last 4 quarters against +25.8%/yr over the last 8 — stabilising; TTM profit −83.3% vs −59.2%/yr — rolling over.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
e.l.f. Beauty, Inc.'s operating margin is −11.1% in the Mar 26 quarter, −23.2 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 4.3% to 14.7%. The current quarter is running below every full year in that window.
The latest quarter's operating margin is −11.1%, −23.2 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 4.3%–14.7%.
🚨 Why the margin moved: operating margin went −23.2 pp year on year while gross margin went +0.6 pp — the loss came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
e.l.f. Beauty, Inc. posted a net loss of $0.1 B in the Mar 26 quarter. Full-year FY26 profit was $0.0 B. The 4-year compound rate is 10.7%. That loss is 11.1% of the quarter's revenue. The same quarter a year earlier earned $0.0 B. 1 of the last 12 reported quarters were loss-making.
Mar 26 profit was $−0.1 B, −266.7% year on year. On the full year, FY26 printed $0.0 B (−72.7%), and the 4-year compound rate is 10.7%.
🚨 Why profit moved: revenue contributed +36.4% and the margin −23.2 pp — the quarter was revenue-led despite a thinner margin.
Pace comparison, last four quarters: profit −76.7% vs revenue +23.8%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 152% of e.l.f. Beauty, Inc.'s reported profit arrived as operating cash — the cash follows the profit. In FY26 that was $0.2 B of operating cash against $0.0 B of profit. After $0.0 B of capital spending, $0.2 B was left as free cash.
FY26: operating cash of $0.2 B against reported profit of $0.0 B, leaving free cash of $0.2 B after $0.0 B of capital spending. Across the last 3 fiscal years the conversion rate is 152% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
e.l.f. Beauty, Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY26 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $0.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
e.l.f. Beauty, Inc. earns a ROE of 3% in FY26. Return on invested capital clears the cost of that capital by −6.4 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 1.8% net margin on 0.69× asset turns.
FY26 ROE is 3%.
🚨 Why the return is what it is — the wiring (FY26): 1.8% net margin × 0.69× asset turns × 2.12× balance-sheet leverage ≈ 2.6% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 5.0% − 11.4% = a −6.4 pp spread. The 11.4% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Dividend
e.l.f. Beauty, Inc. pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.
e.l.f. Beauty, Inc. does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
e.l.f. Beauty, Inc. carries total debt of $0.9 B against shareholder equity of $1.1 B as of Mar 26, a debt-to-equity of 0.81. On the annual view that ratio went from 0.35 in FY22 to 0.81 in FY26. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of $0.9 B against shareholder equity of $1.1 B — a debt-to-equity of 0.81. On the annual view, debt-to-equity went from 0.35 (FY22) to 0.81 (FY26). Read the returns on this page with that leverage in mind.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
13.3% of e.l.f. Beauty, Inc.'s tradable float is currently sold short — a large bloc is positioned against it. At typical trading volumes those positions would take about 2.3 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 13.3% of the float is sold short, and at typical trading volumes it would take about 2.3 days to buy those positions back. A large bloc is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
e.l.f. Beauty, Inc.: the Z-score reads 3.71. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 3.71 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 3.71.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Helen of Troy LimitedHELE | 67.6/100Favorable setup71% evidence | LEADER | 24.3/35 Revenue -2.5% · PAT 100% · OPM change 124.5 pp 71% evidence | 12.4/25 ROCE 3.2% · OPM 15% 76% evidence | 15.8/20 P/E 10.2× · PEG 0.42 65% evidence | 15.1/20 RS sector 16.7% · RS bench 16.7% · 1Y 29.5%12 of 12 weeks ahead 70% evidence |
| Exact sum: 24.3 + 12.4 + 15.8 + 15.1 = 67.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Kenvue Inc.KVUE | 63.9/100Mixed-positive evidence81% evidence | BREAKING OUT | 24.5/35 Revenue -0.1% · PAT 53.6% · OPM change 4.7 pp 83% evidence | 15.0/25 ROCE 3.8% · OPM 19.6% 76% evidence | 14.9/20 P/E 20.6× · PEG 0.38 65% evidence | 9.5/20 RS sector -1.5% · RS bench -1.6% · 1Y -8.4%3 of 12 weeks ahead 100% evidence |
| Exact sum: 24.5 + 15 + 14.9 + 9.5 = 63.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Interparfums, Inc.IPAR | 59.8/100Mixed-positive evidence81% evidence | BREAKING OUT | 15.6/35 Revenue 1.8% · PAT 1.5% · OPM change -0.7 pp 83% evidence | 15.8/25 ROCE 6.3% · OPM 21.5% 76% evidence | 9.9/20 P/E 17.2× · PEG 1.99 65% evidence | 18.5/20 RS sector 17.8% · RS bench 17.4% · 1Y 11%6 of 12 weeks ahead 100% evidence |
| Exact sum: 15.6 + 15.8 + 9.9 + 18.5 = 59.8 · Decision use: Price leads the evidence: RS versus the benchmark is 17.4%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 4Newell Brands Inc.NWL | 56.5/100Thin evidence · provisional58% evidence | BREAKING OUT | 19.1/35 Revenue — · PAT — · OPM change 0.9 pp 45% evidence | 8.4/25 ROCE 3.3% · OPM 2.2% 76% evidence | 9.6/20 P/E 27.8× · PEG — 15% evidence | 19.4/20 RS sector 22.9% · RS bench 21.7% · 1Y 25.6%9 of 12 weeks ahead 100% evidence |
| Exact sum: 19.1 + 8.4 + 9.6 + 19.4 = 56.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 5The Clorox CompanyCLX | 54.4/100Mixed-positive evidence81% evidence | TURNING | 21.1/35 Revenue -3.7% · PAT 8.6% · OPM change 2.7 pp 83% evidence | 15.3/25 ROCE 8.7% · OPM 17.3% 76% evidence | 11.9/20 P/E 16.8× · PEG 1.59 65% evidence | 6.1/20 RS sector -12.3% · RS bench -12.9% · 1Y -16.2%2 of 12 weeks ahead 100% evidence |
| Exact sum: 21.1 + 15.3 + 11.9 + 6.1 = 54.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Spectrum Brands Holdings, Inc.SPB | 52.0/100Mixed-positive evidence81% evidence | TURNING | 21.5/35 Revenue -3.7% · PAT 100% · OPM change 3.2 pp 83% evidence | 8.2/25 ROCE 1.5% · OPM 6.1% 76% evidence | 9.6/20 P/E 14× · PEG 2.17 65% evidence | 12.7/20 RS sector 16.8% · RS bench 17.9% · 1Y 61.5%2 of 12 weeks ahead 100% evidence |
| Exact sum: 21.5 + 8.2 + 9.6 + 12.7 = 52 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Kimberly-Clark CorporationKMB | 51.7/100Mixed-positive evidence81% evidence | BREAKING OUT | 19.5/35 Revenue 0.1% · PAT -18.8% · OPM change 2.5 pp 83% evidence | 16.3/25 ROCE 7.7% · OPM 18.1% 76% evidence | 8.1/20 P/E 15.1× · PEG 2.35 65% evidence | 7.8/20 RS sector -7.1% · RS bench -7.7% · 1Y -18.1%4 of 12 weeks ahead 100% evidence |
| Exact sum: 19.5 + 16.3 + 8.1 + 7.8 = 51.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Magnera CorporationMAGN | 50.0/100Thin evidence · provisional58% evidence | BREAKING OUT | 20.7/35 Revenue 35.3% · PAT — · OPM change 1.6 pp 62% evidence | 5.7/25 ROCE 0.5% · OPM 2.1% 76% evidence | 11.2/20 P/E 12.2× · PEG — 15% evidence | 12.4/20 RS sector 2.6% · RS bench 2.3% · 1Y 7.7%8 of 12 weeks ahead 70% evidence |
| Exact sum: 20.7 + 5.7 + 11.2 + 12.4 = 50 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9Church & Dwight Co., Inc.CHD | 49.3/100Thin evidence · provisional58% evidence | TURNING | 17.7/35 Revenue — · PAT — · OPM change -0.3 pp 45% evidence | 13.6/25 ROCE 3.6% · OPM 19.8% 76% evidence | 9.4/20 P/E 31.2× · PEG — 15% evidence | 8.6/20 RS sector -0.9% · RS bench -0.8% · 1Y 13.3%1 of 12 weeks ahead 100% evidence |
| Exact sum: 17.7 + 13.6 + 9.4 + 8.6 = 49.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 10Colgate-Palmolive CompanyCL | 47.3/100Thin evidence · provisional58% evidence | TURNING | 15.2/35 Revenue — · PAT — · OPM change -3.8 pp 45% evidence | 16.7/25 ROCE 9.5% · OPM 18.1% 76% evidence | 9.3/20 P/E 36.4× · PEG — 15% evidence | 6.1/20 RS sector -3.3% · RS bench -3.1% · 1Y 9.3%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15.2 + 16.7 + 9.3 + 6.1 = 47.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 11The Procter & Gamble CompanyPG | 45.5/100Thin evidence · provisional58% evidence | BASING | 16.7/35 Revenue — · PAT — · OPM change -1.5 pp 45% evidence | 15.8/25 ROCE 4.5% · OPM 21.5% 76% evidence | 9.8/20 P/E 22.2× · PEG — 15% evidence | 3.2/20 RS sector -11.2% · RS bench -11.4% · 1Y -3.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.7 + 15.8 + 9.8 + 3.2 = 45.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12Acme United CorporationACU | 43.6/100Mixed-negative evidence75% evidence | TURNING | 13.9/35 Revenue 4.1% · PAT 0% · OPM change -2 pp 83% evidence | 9.1/25 ROCE 1.1% · OPM 3.3% 76% evidence | 6.0/20 P/E 19.4× · PEG 2.81 65% evidence | 14.6/20 RS sector 16.2% · RS bench 16.3% · 1Y 36.3%3 of 12 weeks ahead 70% evidence |
| Exact sum: 13.9 + 9.1 + 6 + 14.6 = 43.6 · Decision use: Price leads the evidence: RS versus the benchmark is 16.3%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 13Edgewell Personal Care CompanyEPC | 43.0/100Mixed-negative evidence65% evidence | BREAKING OUT | 9.1/35 Revenue 0.4% · PAT -139.1% · OPM change -6 pp 83% evidence | 8.3/25 ROCE 0.6% · OPM 3.5% 76% evidence | 9.1/20 P/E 38.4× · PEG — 15% evidence | 16.5/20 RS sector 21.1% · RS bench 20.9% · 1Y 29.5%7 of 12 weeks ahead 70% evidence |
| Exact sum: 9.1 + 8.3 + 9.1 + 16.5 = 43 · Decision use: Price leads the evidence: RS versus the benchmark is 20.9%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 14Nu Skin Enterprises, Inc.NUS | 39.4/100Thin evidence · provisional58% evidence | BASING | 18.2/35 Revenue -14.2% · PAT — · OPM change 4 pp 62% evidence | 6.2/25 ROCE 0.4% · OPM 1.3% 76% evidence | 11.5/20 P/E 6.6× · PEG — 15% evidence | 3.5/20 RS sector -44.5% · RS bench -45.4% · 1Y -40.3%0 of 12 weeks ahead 70% evidence |
| Exact sum: 18.2 + 6.2 + 11.5 + 3.5 = 39.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 15The Honest Company, Inc.HNST | 36.8/100Thin evidence · provisional58% evidence | FADING | 9.0/35 Revenue -9.5% · PAT — · OPM change -3.4 pp 62% evidence | 4.7/25 ROCE -0.4% · OPM -0.8% 76% evidence | 9.0/20 P/E 61.3× · PEG — 15% evidence | 14.1/20 RS sector 8.6% · RS bench 8.3% · 1Y -1.3%8 of 12 weeks ahead 70% evidence |
| Exact sum: 9 + 4.7 + 9 + 14.1 = 36.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 16The Estée Lauder Companies Inc.EL | 34.1/100Adverse evidence64% evidence | ASLEEP | 14.7/35 Revenue 0.3% · PAT — · OPM change -1.9 pp 62% evidence | 9.4/25 ROCE 1.7% · OPM 6.7% 76% evidence | 8.7/20 P/E 178× · PEG — 15% evidence | 1.3/20 RS sector -14.8% · RS bench -15.1% · 1Y -4.1%1 of 12 weeks ahead 100% evidence |
| Exact sum: 14.7 + 9.4 + 8.7 + 1.3 = 34.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17e.l.f. Beauty, Inc.this pageELF | 31.6/100Adverse evidence81% evidence | BREAKING OUT | 11.5/35 Revenue 24.7% · PAT -76.8% · OPM change -24.5 pp 83% evidence | 6.9/25 ROCE -3.2% · OPM -11.2% 76% evidence | 3.8/20 P/E 137.8× · PEG 5.38 65% evidence | 9.4/20 RS sector -7.5% · RS bench -9.6% · 1Y -13.7%6 of 12 weeks ahead 100% evidence |
| Exact sum: 11.5 + 6.9 + 3.8 + 9.4 = 31.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Coty Inc.COTY | 29.7/100Adverse evidence64% evidence | TURNING | 10.3/35 Revenue -3.6% · PAT — · OPM change -7.4 pp 62% evidence | 4.1/25 ROCE -4.4% · OPM -29% 76% evidence | 8.5/20 P/E 20311× · PEG — 15% evidence | 6.8/20 RS sector -11.9% · RS bench -13.5% · 1Y -38.6%4 of 12 weeks ahead 100% evidence |
| Exact sum: 10.3 + 4.1 + 8.5 + 6.8 = 29.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Oddity Tech Ltd.ODD | 26.0/100Adverse evidence75% evidence | ASLEEP | 9.2/35 Revenue 5.1% · PAT -50.9% · OPM change -28.8 pp 83% evidence | 5.4/25 ROCE -3.9% · OPM -12.9% 76% evidence | 8.4/20 P/E 16.9× · PEG 2.29 65% evidence | 3.0/20 RS sector -55.1% · RS bench -56.8% · 1Y -73.7%2 of 12 weeks ahead 70% evidence |
| Exact sum: 9.2 + 5.4 + 8.4 + 3 = 26 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Unilever PLCUL | 48.4/100Thin evidence · provisional43% evidence | TURNING | 18.2/35 Revenue — · PAT — · OPM change — 12% evidence | 14.3/25 ROCE 4.9% · OPM — 61% evidence | 11.0/20 P/E 12.4× · PEG — 15% evidence | 4.9/20 RS sector -11.1% · RS bench -11.6% · 1Y -6.7%1 of 12 weeks ahead 100% evidence |
| Exact sum: 18.2 + 14.3 + 11 + 4.9 = 48.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is e.l.f. Beauty, Inc.'s stock price today?
e.l.f. Beauty, Inc. trades at $87.8, −24.5% over the past year. The company is valued at $5.0 B. The stock sits at 42% of its 52-week range of $50–$140, +14.1% versus its 200-day average. On the tape, the price is topping out, 2 weeks in. — as of 5 August 2026.
What were e.l.f. Beauty, Inc.'s latest quarterly results?
e.l.f. Beauty, Inc. reported revenue of $0.5 B and a net loss of $0.1 B for the Mar 26 quarter. Revenue rose 36.4% and profit fell 266.7% year on year. Earnings per share were $−0.82. The operating margin was −11.1%, 23.2 pp lower than a year earlier. — as of 5 August 2026.
What is e.l.f. Beauty, Inc.'s revenue?
e.l.f. Beauty, Inc. reported revenue of $0.5 B in the Mar 26 quarter, +36.4% year on year. For the full FY26 fiscal year, revenue was $1.6 B (+25.2%). Over the last 4 years revenue compounded at 43.2% a year. — as of 5 August 2026.
What is e.l.f. Beauty, Inc.'s profit?
e.l.f. Beauty, Inc. earned $−0.1 B of net profit in the Mar 26 quarter, −266.7% year on year. Full-year FY26 profit was $0.0 B. The operating margin ran −11.1% in the latest quarter. — as of 5 August 2026.
What is e.l.f. Beauty, Inc.'s market cap?
e.l.f. Beauty, Inc.'s market capitalisation is $5.0 B at a stock price of $87.8. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.
What is e.l.f. Beauty, Inc.'s P/E ratio?
e.l.f. Beauty, Inc. trades at a P/E of 199.6×, at the 100th percentile of its own 4-year range, against a long-run median of 69.5×. This is a comparison with the stock's own history, not a value call — as of 5 August 2026.
Does e.l.f. Beauty, Inc. pay a dividend?
No — e.l.f. Beauty, Inc. has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 5 August 2026.
Is e.l.f. Beauty, Inc. overvalued?
On its own history, e.l.f. Beauty, Inc. looks expensive against its own history: its P/E of 199.6× sits at the 100th percentile of its 4-year range (long-run median 69.5×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 5 August 2026.
Is e.l.f. Beauty, Inc. growing?
Not right now — e.l.f. Beauty, Inc.'s latest numbers are shrinking: latest-quarter revenue +36.4% year on year, profit −266.7%, and the margin −23.2 pp at −11.1%. The 4-year compound rates are 43.2% (revenue) and 10.7% (profit). The earnings engine currently reads: deteriorating — as of 5 August 2026.
How is e.l.f. Beauty, Inc. performing?
e.l.f. Beauty, Inc. is topping out, 2 weeks in. Its latest quarter's revenue rose 36.4% and profit fell 266.7% year on year. Against the S&P 500 it has been ahead on a trailing-13-week view for 6 weeks. This describes what the data did, not a rating. — as of 5 August 2026.
What stage is e.l.f. Beauty, Inc. in?
Deteriorating — profit and EPS growth are shrinking (profit growth −83.3% latest against +300.0% at its 12-quarter best), ROCE slipping at 5.1%. The read comes from the last 12 quarters of growth (revenue growth +24.4% latest, profit growth −83.3% latest, eps growth −76.2% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 5 August 2026.
Is e.l.f. Beauty, Inc. in an uptrend?
It is stalling — the price is topping out (week 2 of stage 3), trading +14.1% versus its 200-day average and at 42% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.
Is e.l.f. Beauty, Inc. beating the market?
On recent form, yes — e.l.f. Beauty, Inc. has been ahead of the S&P 500 on a trailing-13-week view for 6 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 9.9 years the stock moved +247% against the S&P 500's +257% — behind the index over the full window. — as of 5 August 2026.
Will e.l.f. Beauty, Inc.'s stock price go up?
This page publishes no price forecast for e.l.f. Beauty, Inc. What it measures instead: the stock price is $87.8, the price is topping out 2 weeks in. Its P/E of 199.6× sits at the 100th percentile of its own 4-year range. Direction is not something this site claims to know. — as of 5 August 2026.
Is the market betting against e.l.f. Beauty, Inc.?
Yes — short interest is 13.3% of e.l.f. Beauty, Inc.'s tradable float, about 2.3 days to cover at typical volumes. A crowded short: a large bloc is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.
Does e.l.f. Beauty, Inc. have too much debt?
It is moderate — e.l.f. Beauty, Inc.'s debt-to-equity is 0.81. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 5 August 2026.
What is e.l.f. Beauty, Inc.'s capex?
e.l.f. Beauty, Inc. spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was $0.0 B. — as of 5 August 2026.
What is e.l.f. Beauty, Inc.'s cash flow?
e.l.f. Beauty, Inc. generated $0.2 B of operating cash flow in FY26 and $0.2 B of free cash flow after $0.0 B of capital spending. Reported profit that year was $0.0 B, so operating cash ran ahead of profit. — as of 5 August 2026.
Is e.l.f. Beauty, Inc.'s profit real cash?
Yes — over the last 3 fiscal years, 152% of e.l.f. Beauty, Inc.'s reported profit arrived as operating cash. In FY26, operating cash was $0.2 B against reported profit of $0.0 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 5 August 2026.
How financially safe is e.l.f. Beauty, Inc.?
On the balance sheet, the Z-score reads 3.71 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 5 August 2026.
Where is e.l.f. Beauty, Inc. in its business cycle?
e.l.f. Beauty, Inc.'s FY26 operating margin was 4.3%, against a 5-year band of 4.3%–14.7%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran −11.1%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.
What could break the e.l.f. Beauty, Inc. story?
The sharpest disagreement: the price moved −24.5% in a year while annual EPS moved −77.1% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.
Is e.l.f. Beauty, Inc. a stock worth studying right now?
This is not investment advice. The machine read: e.l.f. Beauty, Inc.'s price has outrun its earnings. −24.5% in a year against EPS −77.1% — the market is paying now for delivery later. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.